Evidence mapPaperPMID 33008306Full record

ArticleBMC geriatrics2020

Impaired kidney function is associated with lower quality of life among community-dwelling older adults : The screening for CKD among older people across Europe (SCOPE) study.

Rada Artzi-Medvedik, Robert Kob, Paolo Fabbietti, Fabrizia Lattanzio, Andrea Corsonello, Yehudit Melzer, Regina Roller-Wirnsberger, Gerhard Wirnsberger, Francesco Mattace-Raso, Lisanne Tap and 11 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC geriatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07309094 (Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07309094 recruitingstarted 2023, after this paper: background citation

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease

Ran2023Enrolled250Registered outcomes15Posted comparisons0ConditionsChronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4ArmsGLP-1 receptor agonist, Other drugs, SGLT2 inhibitor, Tirzepatide
Open the trial in the graph
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. The humanistic burden of focal segmental glomerulosclerosis on patients and care-partners in the United States.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 8 countries.

Rada Artzi-MedvedikDepartment of Nursing, Recanati School for Community Health Professions at the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-sheva, Israel.
Robert KobDepartment of Internal Medicine-Geriatrics, Institute for Biomedicine of Aging, Krankenhaus Barmherzige Brüder, Friedrich-Alexander Universität Erlangen-Nürnberg, Koberger Strasse 60, 90408, Nuremberg, Germany.
Paolo FabbiettiItalian National Research Center on Aging (IRCCS INRCA), Ancona, Fermo and Cosenza, Italy. p.fabbietti@inrca.it.ORCID 0000-0003-2130-3070
Fabrizia LattanzioItalian National Research Center on Aging (IRCCS INRCA), Ancona, Fermo and Cosenza, Italy.
Andrea CorsonelloItalian National Research Center on Aging (IRCCS INRCA), Ancona, Fermo and Cosenza, Italy.
Yehudit MelzerDepartment of Physical Therapy, Recanati School for Community Health Professions at the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-sheva, Israel.
Regina Roller-WirnsbergerDepartment of Internal Medicine, Medical University of Graz, Graz, Austria.
Gerhard WirnsbergerDivision of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Francesco Mattace-RasoDepartment of Internal Medicine, Section of Geriatric Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Lisanne TapDepartment of Internal Medicine, Section of Geriatric Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Pedro GilDepartment of Geriatric Medicine, Hospital Clinico San Carlos, Madrid, Spain.
Sara Lainez MartinezDepartment of Geriatric Medicine, Hospital Clinico San Carlos, Madrid, Spain.
Francesc FormigaGeriatric Unit, Internal Medicine Department, Bellvitge University Hospital - IDIBELL - L'Hospitalet de Llobregat, Barcelona, Spain.
Rafael Moreno-GonzálezGeriatric Unit, Internal Medicine Department, Bellvitge University Hospital - IDIBELL - L'Hospitalet de Llobregat, Barcelona, Spain.
Tomasz KostkaDepartment of Geriatrics, Healthy Ageing Research Centre, Medical University of Lodz, Lodz, Poland.
Agnieszka GuligowskaDepartment of Geriatrics, Healthy Ageing Research Centre, Medical University of Lodz, Lodz, Poland.
Johan ÄrnlövDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Axel C CarlssonDepartment of Medical Sciences, Uppsala University, Uppsala, Sweden.
Ellen FreibergerDepartment of Internal Medicine-Geriatrics, Institute for Biomedicine of Aging, Krankenhaus Barmherzige Brüder, Friedrich-Alexander Universität Erlangen-Nürnberg, Koberger Strasse 60, 90408, Nuremberg, Germany. Ellen.Freiberger@fau.de.
Itshak MelzerDepartment of Physical Therapy, Recanati School for Community Health Professions at the faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-sheva, Israel. itzikm@bgu.ac.il.
SCOPE investigators
Istituto Nazionale di Riposo e Cura per Anziani · ITBellvitge University Hospital · ESBen-Gurion University of the Negev · ILErasmus MC · NLDalarna University · SEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEHospital Clínico San Carlos · ESMedical University of Graz · ATMedical University of Lodz · PLIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

Horizon 2020 Framework Programme 634869
6 · The paper itself

Abstract

backgroundQuality of life (QoL) refers to the physical, psychological, social and medical aspects of life that are influenced by health status and function. The purpose of this study was to measure the self-perceived health status among the elderly population across Europe in different stages of Chronic Kidney Disease (CKD).

methodsOur series consisted of 2255 community-dwelling older adults enrolled in the Screening for Chronic Kidney Disease (CKD) among Older People across Europe (SCOPE) study. All patients underwent a comprehensive geriatric assessment (CGA), including included demographics, clinical and physical assessment, number of medications taken, family arrangement, Geriatric Depression Scale (GDS), Cumulative Illness Rating Scale, History of falls, Lower urinary tract symptoms, and Short Physical Performance Battery (SPPB). Estimated glomerular filtration rate (eGFR) was calculated by Berlin Initiative Study (BIS) equation. Quality of life was assessed by Euro Qol questionnaire (Euro-Qol 5D) and EQ-Visual Analogue Scale (EQ-VAS). The association between CKD (eGFR < 60, < 45 ml or < 30 ml/min/1.73m

resultsCKD was found to be significantly associated with low EQoL-VAS in crude analysis (OR = 1.47, 95%CI = 1.16-1.85 for eGFR< 60; OR = 1.38, 95%CI = 1.08-1.77 for eGFR< 45; OR = 1.57, 95%CI = 1.01-2.44). Such association was no longer significant only when adjusting for SPPB (OR = 1.20, 95%CI = 0.93-1.56 for eGFR< 60; OR = 0.87, 95%CI = 0.64-1.18 for eGFR< 45; OR = 0.84, 95%CI = 0.50-1.42), CIRS and polypharmacy (OR = 1.16, 95%CI = 0.90-1.50 for eGFR< 60; OR = 0.86, 95%CI = 0.64-1.16 for eGFR< 45; OR = 1.11, 95%CI = 0.69-1.80) or diabetes, hypertension and chronic obstructive pulmonary disease (OR = 1.28, 95%CI = 0.99-1.64 for eGFR< 60; OR = 1.16, 95%CI = 0.88-1.52 for eGFR< 45; OR = 1.47, 95%CI = 0.92-2.34). The association between CKD and low EQoL-VAS was confirmed in all remaining multivariable models.

conclusionsCKD may significantly affect QoL in community-dwelling older adults. Physical performance, polypharmacy, diabetes, hypertension and COPD may affect such association, which suggests that the impact of CKD on QoL is likely multifactorial and partly mediated by co-occurrent conditions/risk factors.

Indexed as

Quality of LifeRenal Insufficiency, ChronicAgedAged, 80 and overEuropeFemaleGlomerular Filtration RateHumansIndependent LivingKidneyChronic kidney diseaseOld adultsQuality of life

Identifiers

PMID33008306
PMCPMC7530949
OpenAlexW3090749490

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.